List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific Rapid Diagnostics Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Rapid Diagnostics Market 26
Figure 7. Leading Causes of Death in the World, 2000 and 2019, million 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Rapid Diagnostics Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Rapid Diagnostics Market 39
Figure 13. Breakdown of Asia Pacific Rapid Diagnostics Market by Product, 2021-2031, % of Revenue 44
Figure 14. Asia Pacific Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%) 44
Figure 15. Asia Pacific Rapid Diagnostics Market by Product: Consumables, 2021-2031, $ mn 45
Figure 16. Asia Pacific Rapid Diagnostics Market by Product: Analyzers/Instruments, 2021-2031, $ mn 46
Figure 17. Breakdown of Asia Pacific Rapid Diagnostics Market by Prescription, 2021-2031, % of Sales Revenue 48
Figure 18. Asia Pacific Addressable Market Cap in 2022-2031 by Prescription, Value ($ mn) and Share (%) 48
Figure 19. Asia Pacific Rapid Diagnostics Market by Prescription: Professional Diagnostics, 2021-2031, $ mn 49
Figure 20. Asia Pacific Rapid Diagnostics Market by Prescription: OTC Based Testing, 2021-2031, $ mn 50
Figure 21. Breakdown of Asia Pacific Rapid Diagnostics Market by Platform, 2021-2031, % of Sales Revenue 52
Figure 22. Asia Pacific Addressable Market Cap in 2022-2031 by Platform, Value ($ mn) and Share (%) 52
Figure 23. Asia Pacific Rapid Diagnostics Market by Platform: Immunoassays, 2021-2031, $ mn 53
Figure 24. Asia Pacific Rapid Diagnostics Market by Immunoassays: Lateral Flow Assays, 2021-2031, $ mn 55
Figure 25. Asia Pacific Rapid Diagnostics Market by Immunoassays: Serological Assays, 2021-2031, $ mn 56
Figure 26. Asia Pacific Rapid Diagnostics Market by Immunoassays: Other Immunoassays, 2021-2031, $ mn 57
Figure 27. Asia Pacific Rapid Diagnostics Market by Platform: Molecular Detection, 2021-2031, $ mn 58
Figure 28. Asia Pacific Rapid Diagnostics Market by Molecular Detection: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 59
Figure 29. Asia Pacific Rapid Diagnostics Market by Molecular Detection: Other Molecular Detection Tests, 2021-2031, $ mn 60
Figure 30. Asia Pacific Rapid Diagnostics Market by Platform: Other Platforms, 2021-2031, $ mn 61
Figure 31. Breakdown of Asia Pacific Rapid Diagnostics Market by Application, 2021-2031, % of Revenue 63
Figure 32. Asia Pacific Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 63
Figure 33. Asia Pacific Rapid Diagnostics Market by Application: Blood Glucose Testing, 2021-2031, $ mn 64
Figure 34. Asia Pacific Rapid Diagnostics Market by Application: Cardiometabolic Testing, 2021-2031, $ mn 65
Figure 35. Asia Pacific Rapid Diagnostics Market by Application: Infectious Disease Testing, 2021-2031, $ mn 66
Figure 36. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: COVID-19 Testing, 2021-2031, $ mn 68
Figure 37. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Healthcare-associated Infections (HAI) Testing, 2021-2031, $ mn 69
Figure 38. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Hepatitis Testing, 2021-2031, $ mn 70
Figure 39. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Tropical Diseases Testing, 2021-2031, $ mn 71
Figure 40. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: HIV Testing, 2021-2031, $ mn 72
Figure 41. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Influenza Testing, 2021-2031, $ mn 73
Figure 42. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Sexually Transmitted Diseases (STD) Testing, 2021-2031, $ mn 74
Figure 43. Asia Pacific Rapid Diagnostics Market by Infectious Disease Testing: Other Infectious Diseases Testing, 2021-2031, $ mn 75
Figure 44. Asia Pacific Rapid Diagnostics Market by Application: Blood Coagulation Testing, 2021-2031, $ mn 76
Figure 45. Asia Pacific Rapid Diagnostics Market by Application: Hematology Testing, 2021-2031, $ mn 77
Figure 46. Asia Pacific Rapid Diagnostics Market by Application: Cancer Testing, 2021-2031, $ mn 78
Figure 47. Asia Pacific Rapid Diagnostics Market by Application: Drug Abuse Testing, 2021-2031, $ mn 79
Figure 48. Asia Pacific Rapid Diagnostics Market by Application: Pregnancy & Fertility Testing, 2021-2031, $ mn 80
Figure 49. Asia Pacific Rapid Diagnostics Market by Application: Other Applications, 2021-2031, $ mn 81
Figure 50. Breakdown of Asia Pacific Rapid Diagnostics Market by End User, 2021-2031, % of Revenue 83
Figure 51. Asia Pacific Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 83
Figure 52. Asia Pacific Rapid Diagnostics Market by End User: Hospitals & Clinics, 2021-2031, $ mn 84
Figure 53. Asia Pacific Rapid Diagnostics Market by End User: Laboratories, 2021-2031, $ mn 85
Figure 54. Asia Pacific Rapid Diagnostics Market by End User: Individuals/Homecare, 2021-2031, $ mn 86
Figure 55. Asia Pacific Rapid Diagnostics Market by End User: Other End Users, 2021-2031, $ mn 87
Figure 56. Breakdown of APAC Rapid Diagnostics Market by Country, 2021 and 2031, % of Revenue 89
Figure 57. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 90
Figure 58. Rapid Diagnostics Market in Japan, 2021-2031, $ mn 92
Figure 59. Rapid Diagnostics Market in China, 2021-2031, $ mn 94
Figure 60. Rapid Diagnostics Market in Australia, 2021-2031, $ mn 96
Figure 61. Rapid Diagnostics Market in India, 2021-2031, $ mn 98
Figure 62. Rapid Diagnostics Market in South Korea, 2021-2031, $ mn 100
Figure 63. Rapid Diagnostics Market in Rest of APAC, 2021-2031, $ mn 102
Figure 64. Growth Stage of Asia Pacific Rapid Diagnostics Industry over the Forecast Period 104
Asia Pacific Rapid Diagnostics will grow by 10.9% annually with a total addressable market cap of $ 129,373.7 million over 2022-2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations. Highlighted with 35 tables and 64 figures, this 126-page report “Asia Pacific Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Consumables • Analyzers/Instruments Based on Prescription, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Professional Diagnostics • OTC Based Testing By Platform, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Immunoassays o Lateral Flow Assays o Serological Assays o Other Immunoassays • Molecular Detection o Polymerase Chain Reaction (PCR) o Other Molecular Detection Tests • Other Platforms By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Blood Glucose Testing • Cardiometabolic Testing • Infectious Disease Testing o COVID-19 Testing o Healthcare-associated Infections (HAI) Testing o Hepatitis Testing o Tropical Diseases Testing o HIV Testing o Influenza Testing o Sexually Transmitted Diseases (STD) Testing o Other Infectious Diseases Testing • Blood Coagulation Testing • Hematology Testing • Cancer Testing • Drug Abuse Testing • Pregnancy & Fertility Testing • Other Applications By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals & Clinics • Laboratories • Individuals/Homecare • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Prescription and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott Diagnostics ACON Laboratories Becton Dickinson and Co. BioMérieux S.A. Bio-Rad Laboratories, Inc. Chembio Diagnostic Systems Danaher Corp. F. Hoffmann La Roche Ltd. GlySens Inc. Meridian Bioscience Inc. OraSure Technologies Inc. Siemens Healthineers AG Thermo Fisher Scientific Inc. Trinity Biotech Plc (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More